Daxor Corp Announces New Data From Banner University Medicine Demonstrating Effectiveness Of BVA-100 Use In Ambulatory Heart Failure Patients Presented At Heart Failure Society Of America Annual Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Daxor Corporation (NASDAQ:DXR) has announced new data from Banner University Medicine validating the benefits of the company's BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure. The data was presented at the Annual Scientific Meeting of the Heart Failure Society of America. The study found that the BVA-100 test provided highly effective guidance for care of heart failure patients, with the test identifying variances in red blood cell volumes that provided an opportunity to evaluate and treat these patients.
October 11, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daxor's BVA-100 diagnostic blood test has been validated by new data from Banner University Medicine, demonstrating its effectiveness in guiding the care of heart failure patients. This could potentially increase the demand for Daxor's product.
The validation of Daxor's BVA-100 diagnostic blood test by new data from Banner University Medicine is a positive development for the company. The data demonstrates the test's effectiveness in guiding the care of heart failure patients, which could potentially increase the demand for the product and positively impact Daxor's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100